MedTrace Logo

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

NCT00916760 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2013-11-11

No results posted yet for this study

Summary

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

Depigoid Parietaria judaica 1000DPP/ml

Subcutaneous monthly treatment

BIOLOGICAL

Placebo

Subcutaneous monthly treatment

Sponsors & Collaborators

  • Laboratorios Leti, S.L.

    lead INDUSTRY

Principal Investigators

  • Angel Ferrer, Dr · Hospital Vega Baja

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916760 on ClinicalTrials.gov